Lipigon signs target validation agreement with Secarna Pharma

The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases. 

Read more

High quality line-up great value for both sides at BUID2017

The eight consecutive Biotech Umeå Investment Day attracted almost 30 Swedish and international investors to Blasierummet at Grand Hotel on the 2 of February 2017 in Stockholm. One of the most appreciated aspects of the event was the flexibility to arrange additional ad-hoc partnering meetings and the size and atmosphere at the event.

Read more